In 2016, Oh et al. (NCT01152853: a phase II trial) examined the efficacy, toxicity profile, and potential biomarkers of second-line dacomitinib in 27 pretreated patients with HER2-positive GC [32]. Here, ERBB2 is linked to gastric cancer.